# A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

> **NCT05872269** · PHASE4 · UNKNOWN · sponsor: **Zydus Lifesciences Limited** · enrollment: 1500 (estimated)

## Conditions studied

- NAFLD
- Obesity
- Type 2 Diabetes
- Dyslipidemias
- Metabolic Syndrome

## Interventions

- **DRUG:** Saroglitazar

## Key facts

- **NCT ID:** NCT05872269
- **Lead sponsor:** Zydus Lifesciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-20
- **Primary completion:** 2025-01-10
- **Final completion:** 2025-06-10
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872269, "A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05872269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*